Blockade of the L‐arginine/NO synthase pathway worsens hepatic apoptosis and liver transplant preservation injury

Gautam P. Yagnik, Yoshihito Takahashi, George Tsoulfas, Kaye Reid, Noriko Murase, David A. Geller – 30 December 2003 – Organ graft preservation injury is a major problem complicating liver transplantation. The L‐arginine/nitric oxide pathway has protective effects in several models of liver injury. The purpose of this study was to evaluate the role of the L‐arginine/NO synthase (NOS) pathway on liver preservation injury and to characterize endogenous inducible NOS (iNOS) expression.

Incidence of drug‐induced hepatic injuries: A French population‐based study

Catherine Sgro, François Clinard, Kader Ouazir, Henry Chanay, Christian Allard, Christian Guilleminet, Claude Lenoir, Alain Lemoine, Patrick Hillon – 30 December 2003 – The incidence of hepatic adverse drug reactions (ADRs) remains unknown in the general population. The goal of this population‐based study was to assess the incidence and seriousness of hepatic ADRs.

Human WISP1v, a member of the CCN family, is associated with invasive cholangiocarcinoma

Shinji Tanaka, Keishi Sugimachi, Toshifumi Kameyama, Shin‐ichiro Maehara, Ken Shirabe, Mitsuo Shimada, Jack R. Wands, Yoshihiko Maehara – 30 December 2003 – Family members of the connective tissue growth factor, cysteine‐rich 61, nephroblastoma over‐expressed gene (CCN) encode cysteine‐rich secreted proteins with roles in human fibrotic disorders and tumor progression. In this study, we identified a CCN family member, WISP1v, as over‐expressed in human cholangiocarcinomas. Genetic analysis of WISP1v was performed on surgically resected specimens of cholangiocarcinoma.

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

Giulio Marchesini, Elisabetta Bugianesi, Gabriele Forlani, Fernanda Cerrelli, Marco Lenzi, Rita Manini, Stefania Natale, Ester Vanni, Nicola Villanova, Nazario Melchionda, Mario Rizzetto – 30 December 2003 – Nonalcoholic fatty liver disease (NAFLD) has been associated with the insulin‐resistance syndrome, at present defined as the metabolic syndrome, whose limits were recently set. We assessed the prevalence of the metabolic syndrome in 304 consecutive NAFLD patients without overt diabetes, on the basis of 3 or more criteria out of 5 defined by the U.S.

Inhibition of hepatitis B virus expression and replication by RNA interference

Amir Shlomai, Yosef Shaul – 30 December 2003 – RNA interference (RNAi) is the process of sequence‐specific gene silencing, initiated by double‐stranded RNA (dsRNA) that is homologous in sequence to the target gene. Because it has been shown that RNAi can be accomplished in cultured mammalian cells by introducing small interfering RNAs (siRNAs), much effort has been invested in exploiting this phenomenon for experimental and therapeutic means.

p18(INK4c) collaborates with other CDK‐inhibitory proteins in the regenerating liver

Tom Luedde, Maria E. Rodriguez, Frank Tacke, Yue Xiong, David A. Brenner, Christian Trautwein – 30 December 2003 – p18(INK4c) belongs to the family of cyclin‐dependent kinase inhibitory proteins that target the cyclin‐dependent kinases and inhibit their catalytic activity. The role of p18(INK4c) for cell cycle progression in vivo is characterized poorly. Therefore, we studied the expression and physiologic relevance of p18 in quiescent and proliferating hepatocytes during liver regeneration.

Mouse A6–positive hepatic oval cells also express several hematopoietic stem cell markers

Bryon E. Petersen, Brian Grossbard, Heather Hatch, Liya Pi, Jie Deng, Edward W. Scott – 30 December 2003 – Hepatic oval cells (HOC) are thought to be a type of facultative stem cell that arises as a result of certain forms of hepatic injury. A new and more efficient model has been established to activate the oval cell compartment in mice by incorporating 3,5‐diethoxycarbonyl‐1,4‐dihydro‐collidine (DDC) in a standard chow at a concentration of 0.1%. At the present time, very few markers exist for the mouse oval cells.

Subscribe to